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Abstract
Selective inhibitors of cyclic nucleotide phosphodiesterase-5 (PDE5) have been used as drugs for
treatment of male erectile dysfunction and pulmonary hypertension. An insight into the
pharmacophores of PDE5 inhibitors is essential for development of second generation of PDE5
inhibitors, but has not been completely illustrated. Here we report the synthesis of a new class of the
sildenafil derivatives and a crystal structure of the PDE5 catalytic domain in complex with 5-(2-
ethoxy-5-(sulfamoyl)-3-thienyl)-1-methyl-3-propyl-1,6-dihydro-7H-pyrazolo[4,3-d] pyrimidin-7-
one (12). Inhibitor 12 induces conformational change of the H-loop (residues 660–683), which is
different from any of the known PDE5 structures. The pyrazolopyrimidinone groups of 12 and
sildenafil are well superimposed, but their sulfonamide groups show a positional difference of as
much as 1.5 Å. The structure-activity analysis suggests that a small hydrophobic pocket and the H-
loop of PDE5 are important for the inhibitor affinity, in addition to two common elements for binding
of almost all the PDE inhibitors: the stack against the phenylalanine and the hydrogen bond with the
invariant glutamine. However, the PDE5-12 structure does not provide a full explanation to affinity
changes of the inhibitors. Thus alternatives such as conformational change of the M-loop are open
and further structural study is required.
1. Introduction
Cyclic nucleotide phosphodiesterases (PDEs) are key enzymes that control cellular
concentrations of the second messengers cAMP and cGMP [1–5]. The human genome encodes
21 PDE genes that are categorized into 11 families. Alternative mRNA splicing of the PDE
genes produces about 100 isoforms of PDE proteins that distribute over various cellular
compartments and play vital roles in physiological processes. PDE molecules contain a variable
regulatory domain and a conserved catalytic domain. However, each PDE family shows
characteristic substrate specificity and inhibitor selectivity. Family selective PDE inhibitors
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have been widely studied as therapeutics for treatment of various human diseases, including
cardiotonics, vasodilators, smooth muscle relaxants, antidepressants, antithrombotics,
antiasthmatics, and agents for improvement of learning and memory [6–14].
The most successful examples of this drug class are the PDE5 inhibitors (Fig. 1) sildenafil
(Viagra), vardenafil (Levitra), and tadalafil (Cialis) that are drugs for treatment of male erectile
dysfunction [7]. Sildenafil (Revatio) has additionally been approved for treatment of
pulmonary hypertension [15]. Recently, udenafil (Zydena) has also been approved by Korean
authorities for treatment of male erectile dysfunction [16]. Although four PDE5 inhibitors have
been successfully approved as drugs for treatment of human diseases, enthusiasm for
development of novel PDE5 inhibitors continues. In particular, PDE5 inhibitors have potential
for other applications such as memory improvement, anticancer therapy, and treatment of heart
diseases [13,17–20]. Thus, much recent attention has been given to development of second
generation PDE5 inhibitors that have the same or different scaffolds as the current drugs but
differ in their pharmacokinetic profiles [19].
Several structures of PDE5 in complex with various inhibitors are available [21–25]. However,
an insight into the pharmacophores of PDE5 inhibitors, which is essential for development of
the second generation of PDE5 inhibitors, has not been fully elucidated. For example, the
structures of the PDE5 catalytic domain in complex with sildenafil or vardenafil showed an
unfavorable interaction between these drugs and the invariant Gln817 that is an important
residue for binding of substrate and inhibitors of all PDE families (Fig. 1). In particular, the
distance between the amide oxygen of the Gln817 side chain and the ethoxyphenyl oxygen of
sildenafil or vardenafil in the crystal structures [21,24,25] is typical of a hydrogen bond.
However, both oxygen atoms involved in the contact lack a hydrogen donor for formation of
a hydrogen bond. To explore the possibility of reducing this potentially unfavorable oxygen-
oxygen opposition, we synthesized a series of PDE5 inhibitors in which the alkoxyphenyl ring
of the scaffold is replaced with a 5-membered thiophene ring, characterized the potency of the
inhibitors, and determined a structure of the PDE5 catalytic domain in complex with the
representative compound 12 (Fig. 1). The comparison of PDE5-12 with the known structures
of PDE5-inhibitor complexes provides insight into the pharmacophores of the PDE5 inhibitors
and a structural basis for design of new second generation PDE5 inhibitors.
2. Materials and Methods
2.1. Synthesis of PDE5 inhibitors
A series of sildenafil derivatives featuring a thiophene replacement for the phenyl group were
synthesized using modified literature procedures (Scheme 1) [26–33].
5-(2-bromo-3-thienyl)-1-methyl-3-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]
pyrimidin-7-one (4) [26]—To a suspension of 2-bromothiophene-3-carboxylic acid (414
mg, 2.00 mmol) in anhydrous CH2Cl2 (20 mL) was added SOCl2 (5 mL) and DMF (5 drops).
The mixture was refluxed for 4 hours. After removal of the solvent and excess SOCl2, the crude
acyl chloride was suspended in pyridine (5 mL) and a solution of 4-amino-1-methyl-3-n-
propylpyrazole-5-carboxamide hydrochloride (654 mg, 2.99 mmol) and Et3N (606 mg, 5.99
mmol) in CH2Cl2 (10 mL) was added. After heating at reflux for 2 hours, the reaction mixture
was poured into cold water and extracted with 5% MeOH in CH2Cl2 (3 × 50 mL). The organic
extracts were combined, washed with water and brine, dried over Na2SO4, and evaporated to
a dry solid in vacuo. The crude product was suspended in t-BuOH (25 mL) and t-BuOK (672
mg, 5.99 mmol) was added. The resulting mixture was heated at reflux under nitrogen for 4
hours and then concentrated under vacuum and partitioned between CH2Cl2 and water. The
organic layer was collected and the aqueous layer was further extracted with CH2Cl2 (2 × 50
mL). The combined organic layer was dried over Na2SO4, concentrated under vacuum, and
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then purified by column chromatography (eluting with 2:1 Pet:EtOAc) to afford the title
compound (317 mg, yield: 45%) as a white solid.
Mp: 165–166°C; 1H NMR (300MHz, CD3SOCD3) δ 0.93 (t, J = 7.1, 3H, CH3), 1.72–1.79 (m,
2H, CH2), 2.76 (t, J = 7.2, 2H, CH2), 4.14 (s, 3H, NCH3), 7.32 (d, J = 5.5, 1H), 7.70 (d, J = 5.5
1H), 12.34 (s, 1H); 13C NMR (75MHz, CD3SOCD3) δ 13.76, 21.59, 27.10, 37.77, 113.0, 124.1,
127.4, 128.5, 134.1, 137.2, 144.7, 145.4, 153.8; IR (KBr): 3434, 3152, 2965, 2928, 1693, 1591
cm−1; ESI-MS: m/z = 351 [M−H]−. Anal. Calcd for C13H13BrN4OS: C: 44.20; H: 3.71; N:
15.86; Found: C: 44.38; H: 3.71; N: 15.87.
5-(2-bromo-5-(4-methylpiperazinylsulfonyl)-3-thienyl)-1-methyl-3-propyl-1,6-
dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (5) [27–29]—Compound 4 (177 mg, 0.50
mmol) was added to a mixture of thionyl chloride (1 mL) and chlorosulfonic acid (3 mL) cooled
in an ice-water bath. The resultant mixture was heated to 40°C with stirring for 2 hours and
then quenched by decanting onto ice (50 g). The aqueous mixture was extracted with CHCl3
(2 × 30 mL). The combined organic layer (containing the crude sulfonyl chloride of 4) was
concentrated to 25 mL under vacuum and triethylamine (155 mg, 1.53 mmol) and N-
methylpiperazine (75 mg, 0.75 mmol) were added to the solution. The mixture was stirred
overnight at room temperature. After removal of solvent, the residue was purified by column
chromatography (eluting with 20:1 CHCl3:CH3OH) to afford the title compound (209 mg,
yield: 81%) as a white solid.
Mp: 213–215 °C; 1H NMR (300MHz, CD3SOCD3) δ 0.93 (t, J = 7.2, 3H, CH3), 1.72–1.80 (m,
2H, CH2), 2.18 (s, 3H, NCH3), 2.43 (br s, 4H), 2.77(t, J = 7.2, 2H, CH2), 3.04 (br s, 4H), 4.15
(s, 3H, NCH3), 7.86 (s, 1H), 12.55 (br s, 1H); 13C NMR (75MHz, CD3SOCD3) δ 13.77, 21.61,
27.09, 37.81, 45.06, 45.65, 53.22, 120.4, 124.3, 133.1, 134.6, 135.0, 137.0, 144.1, 144.9, 153.7;
IR (KBr): 3435, 2959, 2852, 1681, 1582 cm−1; ESI-MS: m/z = 513 [M−H]−; Anal. Calcd for
C18H23BrN6O3S2: C, 41.94; H, 4.50; N, 16.30; Found: C, 41.86; H, 4.60; N, 16.25.
5-(2-bromo-5-(sulfamoyl)-3-thienyl)-1-methyl-3-propyl-1,6-dihydro-7H-pyrazolo
[4,3-d]pyri midin-7-one (6)—The crude sulfonyl chloride of 4 was concentrated to 10mL
under vacuum and then added dropwise to cold concentrated ammonia solution (20 mL). The
mixture was stirred at room temperature overnight. After removal of excess solvent, the crude
product was collected by filtration and purified by column chromatography (eluted with
CHCl3:CH3OH = 15:1). The yielded compound in title was a white solid (183 mg, yield: 85%).
Mp: 267–268°C; 1H NMR (300MHz, CD3SOCD3) δ 0.93 (t, J = 7.2, 3H, CH3), 1.71–1.78 (m,
2H, CH2), 2.76(t, J = 7.2, 2H, CH2), 4.15 (s, 3H, NCH3), 7.71 (s, 1H), 7.90 (br s, 2H,
SONH2), 12.52 (s, 1H); 13C NMR (75MHz, CD3SOCD3) δ 13.78, 21.64, 27.08, 37.81, 117.88,
124.3, 130.3, 134.4, 137.0, 144.5, 144.8, 145.3, 153.7; IR (KBr): 3434, 2960, 1676, 1581
cm−1; ESI- MS: m/z = 432 [M−H]−; Anal. Calcd for C13H14BrN5O3S2: C, 36.12; H, 3.26; N,
16.20; Found: C, 36.05; H, 3.26; N, 16.38.
5-(5-(4-methylpiperazinylsulfonyl)-3-thienyl)-1-methyl-3-propyl-1,6-dihydro-7H-
pyrazolo [4,3-d] pyrimidin-7-one (7) [27]—To a solution of compound 5 (60 mg, 0.12
mmol) in methanol (20 mL), zinc dust (23 mg, 0.36 mmol) and formic acid (0.2 mL) were
added. The mixture was stirred overnight. Excess zinc dust was removed by filtration. The
filtrate was concentrated in vacuum, then purified by column chromatography (eluted with
CHCl3:CH3OH = 20:1). The yielded compound in title was a white solid (45 mg, yield: 85%).
Mp: 239–240 °C; 1H NMR (300MHz, CD3SOCD3) δ 0.95 (t, J = 6.8, 3H, CH3), 1.72–1.79 (m,
2H, CH2), 2.25 (s, 3H, NCH3), 2.55 (br s, 4H), 2.79 (t, J = 6.9, 3H), 3.05 (br s, 4H), 4.14 (s,
3H, NCH3), 8.20 (s, 1H), 8.78 (s, 1H), 12.54 (br s, 1H); 13C NMR (125MHz, CD3SOCD3) δ
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13.70, 21.43, 26.93, 37.75, 45.03, 45.61, 53.21, 124.2, 131.5, 133.6, 135.5, 135.9, 137.3,
144.86, 144.91, 154.2; IR (KBr): 3418, 3093, 2934, 1682, 1578 cm−1; ESI-MS: m/z = 435 [M
−H]−. Anal. Calcd for C18H24N6O3S2: C, 49.52; H, 5.54; N, 19.25; Found: C, 49.67; H, 5.60;
N, 19.13.
5-(2-Methoxy-5-(4-methylpiperazinylsulfonyl)-3-thienyl)-1-methyl-3-propyl-1,6-
dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (8) [30]—After sodium (92 mg, 4.00
mmol) was completely dissolved in anhydrous methanol (20 mL), CuI (5 mg) and compound
5 (130 mg, 0.25 mmol) were added to the solution. The mixture was heated and refluxed in
nitrogen for 6 hours. The resulted mixture was concentrated under vacuum. The residue was
partitioned between CH2Cl2 and water. The aqueous layer was further extracted with 5%
MeOH in CH2Cl2 (2 × 30 mL). The combined organic layer was dried over Na2SO4,
concentrated in vacuum, and purified by column chromatography (eluted with CHCl3:CH3OH
= 40:1). The yielded compound in title was a white solid (55 mg, yield: 47%).
Mp: 264–265 °C; 1H NMR (300MHz, CDCl3) δ 1.03 (t, J = 7.2, 3H, CH3), 1.79–1.87 (m, 2H,
CH2), 2.32 (s, 3H, NCH3), 2.56 (br s, 4H), 2.89 (t, J = 7.2, 2H, CH2), 3.20 (br s, 4H), 4.25 (s,
3H, NCH3), 4.26 (s, 3H, OCH3), 8.09 (s, 1H), 9.90 (s, 1H); 13C NMR (75MHz, CDCl3) δ
14.13, 22.48, 27.72, 38.37, 45.74, 46.12, 53.98, 63.03, 115.3, 121.0, 124.1, 132.6, 138.1, 143.8,
146.6, 153.5, 167.7; IR (KBr): 3352, 2965, 1711, 1584 cm−1; ESI-MS: m/z = 465 [M−H]−1;
Anal. Calcd for C19H26N6O4S2: C, 48.91; H, 5.62; N, 18.01; Found: C, 49.85; H, 5.70; N,
18.13.
5-(2-ethoxy-5-(4-methylpiperazinylsulfonyl)-3-thienyl)-1-methyl-3-propyl-1,6-
dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (9)—Compound 9 was prepared by the
same method for compound 8, except for a replacement of methanol with ethanol. It was a
white solid (79 mg, yield: 66%).
Mp: 193–194 °C; 1H NMR (300MHz, CD3SOCD3) δ 0.93 (t, J = 7.2, 3H, CH3), 1.44 (t, J =
6.3, 3H, CH3), 1.71–1.78 (m, 2H, CH2), 2.16 (s, 3H, NCH3), 2.41 (br s, 4H), 2.75 (t, J = 7.2,
2H, CH2), 3.00 (br s, 4H), 4.12 (s, 3H, NCH3), 4.32–4.36 (m, 2H, OCH2), 7.76 (s, 1H); 13C
NMR (75MHz, CD3SOCD3) δ 13.78, 14.36, 21.51, 27.15, 37.69, 45.12, 45.68, 53.27, 72.40,
115.9, 118.1, 124.0, 132.3, 137.5, 144.3, 144.9, 154.2, 168.3; IR (KBr): 3363, 2930, 1699,1588
cm−1; ESI-MS: m/z = 481 [M+H]+; Anal. Calcd for C20H28N6O4S2: C: 49.98; H: 5.87; N:
17.49; Found: C: 49.85; H: 5.96; N: 17.38.
5-(2-cyano-5-(4-methylpiperazinylsulfonyl)-3-thienyl)-1-methyl-3-propyl-1,6-
dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (10) [31]—To a solution of compound 5
(65 mg, 0.13 mmol) in anhydrous DMF (5mL), copper cyanide (17 mg, 0.19 mmol) was added.
The resulted mixture was heated at 150°C under nitrogen for 6 hours, cooled to 100°C, and
poured into a solution of FeCl3.6H2O (81 mg, 0.300 mmol) in water and HCl. After heated to
60°C for 20 minutes, the mixture was allowed to cool to room temperature and then extracted
with 5% MeOH in CH2Cl2 (2 × 50 mL). The combined organic layers were washed twice with
water, dried over Na2SO4, concentrated in vacuum, and then purified by column
chromatography (eluted with EtOAc:CH3OH = 15:1). The yielded compound in title was a
white solid (12 mg, yield: 20%).
Mp: 234–235 °C; 1H NMR (300MHz, CD3SOCD3) δ 0.92 (t, J = 7.0, 3H, CH3), 1.77–1.84 (m,
2H, CH2), 2.18 (s, 3H, NCH3), 2.43 (br s, 4H), 2.79 (t, J = 7.0, 2H, CH2), 3.11 (br s 4H), 4.16
(s, 3H, NCH3), 8.39 (s, 1H); 13C NMR (75MHz, CD3SOCD3) δ 13.59, 21.34, 27.12, 37.78,
44.98, 45.59, 53.20, 112.0, 112.1, 113.6, 130.9, 136.9, 141.3, 142.3, 143.0, 145.5, 153.9; IR
(KBr): 3430, 2927, 2217, 1680, 1578 cm−1; ESI-MS: m/z = 460 [M−H]−; Anal. Calcd for
C19H23N7O3S2: C, 49.44; H, 5.02; N, 21.24; Found: C: 49.53; H: 5.09; N: 21.13.
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methyl-3-propyl-1, 6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (11) [32]—After
compound 5 (65 mg, 0.13 mmol) was dissolved in DMF (5 mL), Pd(OAc)2 (3 mg, 0.013 mmol),
DPPF (14mg, 0.026 mmol), Cs2CO3 (42 mg, 0.13 mmol), and N-methylpiperazine (16 mg,
0.16 mmol) were added. The resulted mixture was heated at 120°C in nitrogen with stirring
for 6 hours, allowed to cool to room temperature, poured into water, and extracted with ethyl
acetate (150mL). The organic extract was washed with water for three times, dried over
Na2SO4, and then concentrated in vacuum. The residue was purified by column
chromatography (eluted with CHCl3:CH3OH = 20:1). The yielded compound in title was a
white solid (55 mg, yield: 79%).
Mp: 187–188°C; 1H NMR (300MHz, CD3SOCD3) δ 0.96 (t, J = 7.2, 3H, CH3), 1.71–1.78 (m,
2H), 2.19 (s, 3H, NCH3), 2.23 (s, 3H, NCH3), 2.43 (br s, 4H), 2.50 (br s, 4H), 2.77 (t, J = 7.2,
2H, CH2), 3.00 (br s, 4H), 3.13 (br s, 4H), 4.14 (s, 3H, NCH3), 7.70 (s, 1H), 12.14 (s,
1H); 13C NMR (75MHz, CD3SOCD3) δ 13.82, 21.71, 27.05, 37.74, 45.05, 45.32, 45.63, 52.23,
53.25, 53.68, 117.4, 119.9, 124.0, 134.1, 137.2, 144.5, 145.5, 153.5, 163.1; IR (KBr): 3432,
2940, 1698, 1582 cm−1; ESI-MS: m/z = 533 [M−H]−; Anal. Calcd for C23H34N8O3S2: C:
51.66; H: 6.41; N: 20.96; Found: C: 51.76; H: 6.38; N: 20.91.
5-(2-ethoxy-5-(sulfamoyl)-3-thienyl)-1-methyl-3-propyl-1,6-dihydro-7H-pyrazolo
[4,3-d]pyri midin-7-one (12)—Compound 12 was prepared by the same method for
compound 8 except for the replacement of methanol and compound 5, respectively with ethanol
and compound 6. It was a white solid (56 mg, yield: 56%).
Mp: 255–256 °C; 1H NMR (300MHz, CD3SOCD3) δ 0.94 (t, J = 6.8, 3H, CH3), 1.46 (t, J =
6.3, 3H), 1.73–1.78 (m, 2H, CH2), 2.76 (t, J = 7.0, 2H, CH2), 4.13 (s, 3H, NCH3), 4.34 (m, 2H,
OCH2), 7.69 (s, 1H), 7.69 (br s, 2H, SONH2), 11.37 (s, 1H); 13C NMR (75MHz,
CD3SOCD3) δ 13.79, 14.41, 21.59, 27.10, 37.79, 72.36, 113.7, 123.8, 128.5, 129.6, 137.4,
144.5, 144.6, 153.2, 166.3; IR (KBr): 3332, 3089, 2969, 1684, 1587 cm−1; ESI–MS: m/z =
396 [M−H]−; Anal. Calcd for C15H19N5O4S2: C, 45.33; H, 4.82; N, 17.62; Found: C, 45.29;
H, 4.75; N, 17.70.
5-(5-(sulfamoyl)-3-thienyl)-1-methyl-3-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]
pyrimidin-7-one (13) [27]—To a solution of compound 6 (200mg, 0.46 mmol) in methanol
(20 mL), zinc dust (90 mg, 1.38 mmol) and formic acid (0.2 mL) were added. The mixture was
stirred overnight. Excess zinc dust was removed by filtration. The filtrate was concentrated in
vacuum and then purified by column chromatography (eluted with CHCl3:CH3OH = 20:1).
The yielded compound in title was a white solid (133 mg, yield: 82%).
Mp: 307–308°C; 1H NMR (300MHz, CD3SOCD3) δ 0.95 (t, J = 6.9, 3H, CH3), 1.73–1.80 (m,
2H), 2.79 (t, J = 7.2, 2H), 4.14 (s, 3H, NCH3), 7.83 (br s, 2H), 8.15 (s, 1H), 8.63 (s, 1H), 12.51
(br s, 1H); 13C NMR (75MHz, CD3SOCD3) δ 13.78, 21.54, 27.05, 37.77, 124.1, 129.0, 130.4,
134.5, 137.2, 144.6, 145.0, 146.2, 154.1. IR (KBr): 3294, 2958, 1680, 1579 cm−1; ESI–MS:
m/z = 352 [M−H]−; Anal. Calcd for C13H15N5O3S2: C: 44.18; H: 4.28; N: 19.82; Found: C:
44.15; H: 4.20; N: 19.86.
5-(5-(N-butyloxycarbonylaminosulfonyl)-3-thienyl)-1-methyl-3-propyl-1,6-
dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (14) [33]—Compound 13 (65 mg,
0.18mmol) was dissolved in pyridine (4 mL) and 4-dimethylaminopyridine (44 mg, 0.36 mmol)
was added. The solution was cooled in ice bath and butyl chloroformate (40µL, 0.31mmol)
was added. After stirred at room temperature overnight, the mixture was added by HCl (1N,
50 mL) and extracted with ethyl acetate (2×50 mL). The combined organic layers were washed
with HCl (1N) and brine, dried over Na2SO4, concentrated in vacuum, and then purified by
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column chromatography (eluted with CHCl3:CH3OH = 30:1). The yielded compound in title
was a white solid (50 mg, yield: 61%).
Mp: 317–318 °C (dec.); 1H NMR (500MHz, CD3SOCD3) δ 0.83 (t, J = 7.2, 3H, CH3), 0.95
(t, J = 6.9, 3H, CH3), 1.23–1.30 (m, 2H, CH2), 1.49–1.54 (m, 2H, CH2), 1.73–1.80 (m, 2H,
CH2), 2.79 (t, J = 7.2, 2H, CH2), 4.04 (t, J=5.7, 2H, OCH2), 4.14 (s, 3H, NCH3), 8.30 (s, 1H),
8.78 (s, 1H), 12.55 (s, 1H); 13C NMR (125MHz, CD3SOCD3) δ13.26, 13.69, 18.20, 21.46,
26.97, 29.91, 37.75, 65.75, 124.3, 132.6, 133.8, 134.6, 137.3, 140.5, 144, 8, 144.9, 151.0, 154.2;
IR (KBr): 3437, 2961, 1755, 1681, 1584 cm−1; ESI-MS: m/z = 452 [M−H]−; Anal. Calcd for
C18H23N5O5S2: C, 47.67; H, 5.11; N, 15.44; Found: C, 47.54; H, 5.17; N, 15.45.
5-(5-(N-propyloxycarbonylaminosulfonyl)-3-thienyl)-1-methyl-3-propyl-1,6-
dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (15)—Compound 15 was prepared from
compound 13 by the same procedure for compound 14, except for a replacement of butyl
chloroformate with propyl chloroformate. Yield: 65%.
Mp: 312–313 °C (dec.); 1H NMR (300MHz, CD3SOCD3) δ 0.84 (t, J = 6.9, 3H, CH3), 0.95
(t, J = 6.6, 3H, CH3), 1.52–1.59 (m, 2H, CH2), 1.72–1.79 (m, 2H, CH2), 2.79 (t, J = 6.6, 2H,
CH2), 4.00 (t, J = 5.4, 2H, OCH2), 4.14 (s, 3H, NCH3), 8.31 (s, 1H), 8.79 (s, 1H), 12.57 (s,
1H); 13C NMR (125MHz, CD3SOCD3) δ9.84, 13.69, 21.31, 21.47, 26.96, 37.74, 67.50, 124.3,
132.7, 133.8, 134.7, 137.3, 140.5, 144.8, 144.9, 151.0, 154.2; IR (KBr): 3429, 2963, 1748,
1681, 1584 cm−1; ESI-MS: m/z = 438 [M−H]−; Anal. Calcd for C17H21N5O5S2: C, 46.46; H,
4.82; N, 15.93; Found: C, 46.35; H, 4.85; N, 15.87.
5-(5-(N-isopropyloxycarbonylaminosulfonyl)-3-thienyl)-1-methyl-3-propyl-1,6-
dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (16)—Compound 16 was prepared from
compound 13 by the same procedure for compound 14, except for a replacement of butyl
chloroformate with isopropyl chloroformate. Yield: 57%.
Mp: 309–310 °C (dec.); 1H NMR (500MHz, CD3SOCD3) δ 0.95 (t, J = 6.9, 3H, CH3), 1.17–
1.19 (m, 6H), 1.72–1.79 (m, 2H, CH2), 2.79 (t, J = 6.9, 2H, CH2), 4.13 (s, 3H, NCH3), 4.79–
83 (m, 1H, OCH), 8.30 (s, 1H), 8.78 (s, 1H), 12.54 (s, 1H); 13C NMR (125MHz,
CD3SOCD3) δ13.70, 21.32, 21.50, 26.98, 37.75, 70.27, 124.3, 132.7, 133.6, 134.6, 137.3,
140.7, 144.8, 144.9, 150.5, 154.2; IR (KBr): 3444, 2961, 1746, 1682, 1584 cm−1; ESI-MS: m/
z = 438 [M−H]−; Anal. Calcd for C17H21N5O5S2: C, 46.46; H, 4.82; N, 15.93; Found: C, 46.55;
H, 4.76; N, 15.82.
2.2. Characterization of synthesized inhibitors
Melting points were determined on an X-4 microscopic melting point apparatus (Beijing TaiKe
Co., Ltd). Infrared spectra were recorded on a Thermo Nicolet 330FT-IR
spectrophotometer. 1H NMR and 13C NMR spectra were recorded at room temperature in a
Varian Mercury-Plus 300 (compounds 4–6, 8–13) or Varian INOVA 500NB (compounds 7,
14–16), with solvent CDCl3 or CD3SOCD3 as the reference for the chemical shifts.
Electrospray ionization-mass spectra (ESI-MS) were measured in a Shimadzu LCMS-2010A
liquid chromatography mass spectrometer. Flash column chromatography was performed with
silica gel (200–300 mesh, Qingdao Haiyang Chemical). Analytical thin-layer chromatography
was performed on Merck silica gel GF254 plate. Element analysis was carried out in an
Elementar Vario EL.
2.3. Protein expression and purification of PDE5A1
The cDNA of the catalytic domain of human PDE5A1 was generated by the site-directed
mutagenesis of the bovine PDE5A gene as previously described [25]. The coding region for
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amino acids 535–860 of PDE5A1 was amplified by PCR and subcloned into the expression
vector pET15b. The resultant plasmid pET-PDE5A1 was transferred into E. coli strain BL21
(CodonPlus) for overexpression. The E. coli cell carrying pET-PDE5A1 was grown in LB
medium at 37°C to absorption A600 = 0.7 and then 0.1 mM isopropyl β-D-
thiogalactopyranoside was added for further growth at 15°C overnight. Recombinant PDE5A1
was passed through a Ni-NTA column (Qiagen), subjected to thrombin cleavage, and further
purified by passing through Q-Sepharose and Sephacryl S300 columns (Amersham
Biosciences). A typical batch of purification yielded over 10 mg PDE5A1 with a purity >95%
from a 2-liter cell culture.
The cDNA for expression of the full-length human PDE5A1 (residues 1–875) was a gift from
Dr. Corbin at Vanderbilt University and was subcloned into vector pET32a. Protein expression
and purification of the full-length PDE5A1 followed a similar protocol for preparation of the
catalytic domain of PDE5A1.
2.4. Assay of phosphodiesterase activity
The full length human PDE5A1 was used to measure the kinetic properties of synthesized
inhibitors. PDE5A1 was incubated with a reaction mixture containing 20 mM Tris.HCl, pH
7.5, 10 mM MgCl2, 0.5 mM DTT, 3H-cGMP (20000 cpm/assay) at room temperature for 15
min. The reaction was terminated by addition of 0.2 M ZnSO4 and 0.2 M Ba(OH)2. The
product 3H-GMP was precipitated by BaSO4 while unreacted 3H-cGMP remained in the
supernatant. Radioactivity in the supernatant was measured by liquid scintillation counting.
For the measurement of inhibition, at least six concentrations of inhibitors were used together
with a substrate concentration at one tenth of KM and a suitable enzyme concentration. The
IC50 values are the concentrations of inhibitors where 50% enzymatic activity is inhibited.
2.5. Protein crystallization and structure determination
The co-crystals of the PDE5A1 (535–860) catalytic domain in complex with compound 12
were grown by vapor diffusion. The PDE5A1-12 complex was prepared by mixing 1 mM
compound 12 with 15 mg/mL PDE5A1 that was stored in a buffer of 20 mM Tris.base, pH
7.5, 50 mM NaCl, 1 mM β-mercaptoethanol, and 1 mM EDTA. The protein drop was prepared
by mixing 2 µl protein with 2 µl well buffer and crystallized against a well buffer of 2.0 M
sodium formate, 0.1 M sodium citrate, pH 5.6, 5% ethanol at 25°C. The PDE5A1-12 crystals
had the space group P3121 with cell dimensions of a = b = 73.8 and c = 132.5 Å (Table 1).
Diffraction data were collected on beamline X29 at Brookhaven National Laboratory and
processed by program HKL [34].
The PDE5A1–12 structure was solved by molecular replacement with program AMoRe [35],
using the PDE5A1-IBMX structure without the H-loop (residues 660–683) and IBMX as the
initial model. The rotation and translation searches for the crystal of PDE5A1-12 yielded a
correlation coefficient of 0.74 and R-factor of 0.31 for 3054 reflections between 4 to 8 Å
resolution. The atomic model was rebuilt by program O [36] against the electron density maps
that were improved by the density modification package of CCP4. The structure was refined
by CNS (Table 1) [37].
3. Results
3.1. Conformational changes of PDE5A1 upon inhibitor 12 binding
The crystal of PDE5A1 in complex with newly synthesized inhibitor 12 (IC50 = 110 nM)
contains a monomer of the PDE5A1 catalytic domain (residues 535–860) in the asymmetric
unit. Most residues in the PDE5A1-12 structure have solid electron density and are traced
without ambiguity. The PDE5A1-12 structure consists of 15 α-helices that assemble into a
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topological fold common to the known structures of PDE5 and the other PDE families (Fig.
2). The structural superposition of PDE5A1-12 over other PDE5 structures without the H-loop
yielded RMSDs of 0.32, 0.32, 0.43, and 0.29 Å, respectively for the unliganded PDE5A1 and
its complexes with IBMX, icarisid II, and sildenafil, thus indicating the overall similarity
among the PDE5 structures. However, the PDE5A1-12 structure shows characteristic
conformation changes in the H- and M-loops.
The H-loop of PDE5 (residues 660–683) was previously shown to undergo dramatic positional
and conformational changes upon inhibitor binding [25]. Four different conformations were
identified for the H-loop of PDE5A1: a coil in the unliganded state, two short α-helices in the
IBMX complex, a 310 helix in the sildenafil complex, and two short β-strands in the icarisid
II complex (Fig. 2). In addition, the H-loops in these complexes showed positional movements
of as much as 7, 24, and 35 Å, respectively [25]. The H-loop in the PDE5A1-12 structure
contains 310- and α-helices at positions 664–667 and 672–676, corresponding to two short α-
helices H8 and H9 in the PDE5-IBMX complex [25], but differing from the other PDE5
structures. In addition, the H-loop of PDE5A1-12 has positional differences of as much as 5
Å from that of the unliganded PDE5A1 and 7 Å from that of the PDE5A1-IBMX structure
(Fig. 2). Since the PDE5A1-12 crystal has similar unit cell parameters and the same space
group as the unliganded form and the IBMX complex, the different positions and conformations
of the H-loop in these structures must be the consequence of the inhibitor binding, rather than
an artifact of crystal packing.
Residues 793–807 of the M-loop, a region spanning the sequence 788–811, are disordered in
the PDE5A1–12 structure, as are those in the unliganded as well as IBMX- and vardenafil-
bound structures [25,38]. In contrast, the ordered M-loops in the PDE5-sildenafil and PDE5-
icarisid II complexes contact the inhibitors with Leu804 and have similar conformation to those
in the structures of other PDE families [4]. A possible explanation for the M-loop disorder in
the PDE5A1-12 structure might be a lack of direct interactions of the inhibitor 12 with the M-
loop. However, bound sildenafil and icarisid II might also indirectly enhance the
conformational stability of the M-loop by inducing movement of the H-loop and its consequent
packing against residues in the M-loop.
3.2. Binding of inhibitor 12
Inhibitor 12 binds to a pocket next to the divalent metal ions, but does not directly interact with
the metals (Fig. 3). The pyrazolopyrimidinone group of 12 stacks against Phe820 of PDE5A1
and also contacts residues His613, Leu765, Ala767, Ile768, Leu782, Phe786, and Gln817. The
O7 and N6 atoms of pyrazolopyrimidinone (Fig. 3) form two hydrogen bonds with Ne2 and
Oe1 of Gln817, respectively. The ethoxythiophene group interacts via van der Waals forces
with Ala779, Val782, Ala783, Phe786, Met816, Gln817, and Phe820. The ether oxygen of
ethoxythiophene is located at a distance of 2.94 Å from the amide oxygen of the Gln817 side
chain. This distance suggests an unfavorable interaction because neither oxygen carries a
hydrogen donor required for formation of a hydrogen bond. In principle, 180° rotation of the
terminal amide of Gln817 might support binding of inhibitor 12 in its
hydroxypyrazolopyrimidine tautomeric state. Such a binding mode might then also establish
a favorable hydrogen bonded interaction between the inhibitor's ethoxy oxygen and the amide
Ne2 of Gln817. The failure to adopt this binding mode may be influenced by the preferential
stability of the pyrazolopyrimidinone tautomer of 12 as well the protein's internal hydrogen
bonded network that biases the rotameric preferences of Gln817 through interaction with
Gln775. Most of the inhibitor's sulfonamide group (−SO2NH2) makes no contact with the
protein, although its nitrogen is located within van der Waals contact distance of the intra-helix
carbonyl oxygen of Met816. In addition, two water molecules bind to O7 and N2 of 12 (Fig.
3) and bridge respectively to Ne2 of Gln775 and carbonyl oxygen of Asp764.
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The conformation and interaction of inhibitor 12 are comparable with those of sildenafil. Indeed
structural superposition between PDE5A1-12 and PDE5A1-sildenafil shows that the two
pyrazolopyrimidinone groups of the inhibitors not only occupy the same position but also have
the same conformation (Fig. 3). The thiophene ring of inhibitor 12 co-planes with the phenyl
group of sildenafil, but slightly shifts toward the invariant Gln817 (Fig. 3) so that the ethoxy
groups of the two inhibitors are superimposed well. As a result, the sulfonamide group shows
a significant positional displacement of 1.5 Å between the sulfur atoms of 12 and sildenafil.
The binding of the pyrazolopyrimidinone core of 12 also more or less simulates the binding of
IBMX, a non-selective PDE inhibitor. The xanthine skeleton of IBMX co-planes with the
pyrazolopyrimidinone of 12 and the isobutyl group of IBMX is located in the same pocket as
the propyl group of 12 (Fig. 3). Although the orientation of the xanthine is reversed with respect
to the pyrazolopyrimidinone of 12, its O6 and N7 centers occupy roughly the positions of O7
and N6 of the pyrazolopyrimidinone and form two hydrogen bonds with Gln817.
Although the binding of compound 12 causes movement of the H-loop, with atoms displaced
as much as 5 Å from their corresponding positions in the unliganded form, the active site in
the PDE5A1-12 structure is still open (Fig. 3), resembling that of the unliganded or IBMX-
bound forms. The solvent accessible area of 12 is 18.5%. In comparison, sildenafil induces
profound movement of the H-loop as much as 24 Å from that in the unliganded PDE5 structure.
As a result, the active site of PDE5A1 is transformed into a closed form and sildenafil is buried
in the pocket, with a solvent accessible surface of only 9.4% [25].
3.3. Structure and activity relationships suggest that a hydrophobic pocket is critical for the
PDE5 inhibitor binding
Internal and external bond angles for a symmetrical 5-membered ring are respectively 108°
and 126°, whereas the corresponding angles for a 6-membered ring are 120°. The bond angle
difference between 5- and 6-membered rings might, in principle, relax oxygen-oxygen
opposition between the sildenafil ethoxy group and Gln817 upon replacement of the inhibitor's
ethoxyphenyl by an ethoxythiophene subunit. Such a replacement might therefore be expected
to improve the interaction with Gln817 if other parts of the structure remain unchanged. In
contrast to this expectation, the direct thiophene-for-phenyl replacement analogue, compound
9 (IC50 = 1350 nM, Table 2), showed far weaker affinity as an inhibitor than the parent sildenafil
(IC50 = 3.5 nM), with a 386-fold loss of activity. To explore the basis for this unexpected
affinity deterioration, the pharmacophore was investigated by variation of thiophene ring
substituents R1 and R2 for structure-activity analysis.
When R2 is −NH2, compound 12 with R1 = −OEt has about 60-fold better affinity than
compound 13 that has R1 = −H (Table 2). This affinity difference could be explained on the
basis of the crystal structures [21–25], in which R1 orients to a small hydrophobic pocket
comprising residues Glu780, Ala783, Phe787, Ile813, and Met816 (Fig. 3d). Thus, the van der
Waals contact of the ethyl group with the pocket will significantly enhance the binding affinity.
The significance of this hydrophobic interaction is further emphasized by comparison of
UK-122764 and sildenafil. UK-122764 lacks the piperazine-sulfonamide tail, but has a propyl
group in the place of the ethyl group (Fig. 1). Since the methylpiperazine of sildenafil forms
van der Waals interactions with Asn662, Ser663, Tyr664, Ile665, Leu804, and Phe820 in the
crystal structure of PDE5A1-sildenafil [25], truncation of the extended tail subunit in
UK-122764 would be expected to result in significant loss of affinity. However, the IC50 of
UK-122764 is only 5-fold weaker than that of sildenafil [39,40]. This unexpected affinity
change of UK-122764 might be attributed to the better fit of the propyl group than the ethyl
group in the small hydrophobic pocket. Therefore, optimal occupancy of this small
hydrophobic pocket is a key determinant for high binding affinity of PDE5 inhibitors.
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When R2 is methylpiperazine, compound 7 (R1 = −H) shows higher affinity than compounds
8–11 (Table 2). The weak binding of compound 11 can be simply explained by the fact that
R1 = methylpiperazine is too large to fit into the small hydrophobic pocket (Fig. 3d). However,
the factors underlying the observed structure-IC50 relationship for compounds 7–10 are
complicated. Apparently, R1 is involved in two types of interactions: hydrophobic interaction
with the small pocket and a polar contact with the invariant glutamine. Thus, a suitably sized
hydrocarbon chain in R1 would be expected to favor binding of the compound, as seen with
compound 9, where inhibitory potency is slightly better than compounds 8, 10, and 11. The
absence of a substituent at the R1 position will tend to compromise affinity by loss of favorable
interactions within the hydrophobic pocket. On the other hand, the absence of this group also
relieves repulsion with Gln817 (Fig. 1), offsetting the loss in affinity caused by removal of the
contact with the hydrophobic pocket. These factors combine to give a 3-fold affinity difference
between compounds 7 and 9. In short, the interaction of R1 with the small hydrophobic pocket
and also with the invariant glutamine is important for affinity of PDE5 inhibitors.
3.4. Conformational change of the H-loop is apparently a factor for PDE5 inhibition
The structural studies of this PDE5–12 and other PDE5 complexes [25] suggest that
conformational and positional changes of the H-loop are involved in the mechanism of PDE5
inhibition and function. The H-loops in the unliganded state and in the 12- or IBMX-bound
structures occupy similar locations, but have relative displacements of several Angstroms and
different conformations. Since these weakly-bound inhibitors do not directly contact the H-
loop, the conformational changes of the H-loop must be achieved via an allosteric mode,
although the exact path needs further study. In contrast, the large inhibitors, icarisid II and
sildenafil, directly interact with and drag the H-loop to cover up the catalytic pocket. This
modification of the active site inactivates PDE5 and may thus impact on the in vivo function
of PDE5.
The structure-activity study suggests that the conformation and position of the H-loop are a
factor for the function of PDE5 inhibitors, in addition to pi-stacking of inhibitors against the
conserved phenylalanine and hydrogen bonding to the invariant glutamine [4,22,25]. When
R1 is a hydrogen atom, the inhibitors with a large substituent at the R2 position have better
affinity, as shown by 3.5–13 fold higher affinity of compound 7 over compounds 13–16 (Table
2). This might be explained by the van der Waals interactions of the methylpiperazine group
with the H-loop residues of Asn662, Ser663, Tyr664, Ile665, as well as with Leu804 and
Phe820 in a manner similar to the interactions of sildenafil in the crystal structure of PDE5A1-
sildenafil [25].
However, when R1 is an ethoxy group, compound 12 with R2 = −NH2 has about 12-fold better
affinity than compound 9 that has R2 = methylpiperazine. The explanation of this inconsistent
contribution of the tail is not clear. While the sulfonamide (−SO2NH2) nitrogen of 12 makes
favorable ven der Waals interactions with the carbonyl oxygen of Met816, compound 9 might
not be able to form the same contact so as to cause the loss of 12-fold affinity. Since the majority
of residues interacting with the tails of the inhibitors come from the H-loop, the position and
conformation of the H-loop must be a factor for affinity of PDE5 inhibitors. This assumption
is supported by the observation that the H-loop in the PDE5 structure in complex with
vardenafil, which has similar chemical structure but substantially higher affinity than sildenafil,
showed dramatically different conformation from that in the PDE5-sildenafil structure [38].
Clearly the M-loop also contributes to the binding of extended inhibitor structures, as shown
by the interaction of Leu804 with both sildenafil and icarisid II. Given that the H-loop folds
over the M-loop in the co-crystal structures of these latter compounds with PDE5, it is likely
that the interactions between bound inhibitor and residues in the two loops are not independent.
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While the PDE5 inhibitors sildenafil, vardenafil, and tadalafil have been successfully used to
treat erectile dysfunction, interest continues in the development of second generation PDE5
inhibitors for new applications such as cancer and cardiovascular disease. The structure-
activity study in this paper suggests that the conformational variation of the H-loop and a small
hydrophobic pocket are two factors for PDE5 inhibitor binding, in addition to two common
elements of the hydrophobic stack against the phenylalanine and the hydrogen bonds with the
invariant Gln817 [4]. However, the structural information of PDE5-12 could not fully explain
all the observed changes in inhibitory potency of the compounds in this study. For example,
the substitution of EtO for H in R1 when R2 consists of the piperazine group (compounds 13
to 12 in Table 2) generates a 60-fold increase in affinity. This could apparently be explained
with the "hydrophobic pocket" stabilizing the EtO group. However, the same substitution in
R1 when R2 consists of a piperazine group (compounds 7 and 8) causes a 3-fold decrease in
affinity, inconsistent with the simple hydrophobic model. Another example is the 390-fold loss
in binding affinity of analogue 9 in comparison to its parent sildenafil, resulting from the
substitution of the thiophene ring. The structural comparison of the inhibitors (Fig. 3C) suggests
that the five-membered ring of 12 superimposed well with the 6-member ring of sildenafil, but
caused 1.5 Å positional movement of the sulfur atom of the sulfonamide group. However, this
shift does not appear to generate obvious steric constraints that would prevent the piperazine
ring of inhibitor 9 from occupying similar space for the corresponding sildenafil ring.
Therefore, other explanations are open. For example, optimal interactions of the piperazine-
sulfonamide tail with the H- and M-loops cannot be achieved in the inhibitors with the 5-
membered ring whilst accommodating the ethoxy group to balance the favorable interactions
in the hydrophobic pocket against the unfavorable contact with Gln817. Another element for
the inhibitor affinity may be the conformational change of the M-loop and possible corporative
conformational changes of the H- and M-loops. However, the disorder of the M-loop in the
PDE5-12 structure does not allow a rational explanation, and thus further structural studies are
needed.
In short, analysis of the structure and affinity relationships for compounds 7–16 suggests that
the 6-membered phenyl ring in sildenafil is the key to correctly positioning the sulfonamide
group and is thus required for high affinity binding to PDE5. Since the 5-membered thiophene
replacement does not improve the interaction with the invariant glutamine, repositioning the
ethoxy group from the ortho- to the meta-position of the phenyl ring would be a future
consideration to keep the favored hydrophobic interaction, but avoid of the repulsion with the
glutamine.
Accession code
The coordinates and structural factors have been deposited into the Protein Data Bank with
accession code of 3BJC.
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Chemical structures of the PDE5 inhibitors and the interaction of sildenafil with Gln817.
Sildenafil, vardenafil, tadalafil and udenafil are drugs for treatment of erectile dysfunction.
Compound 12 is an inhibitor synthesized for this study. IBMX is a non-selective inhibitor of
most PDE families.
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PDE5 structures. (A) Ribbon diagram. The cyan ribbons represent the comparable structures
of the PDE5 complexes. The H-loops are shown in green for PDE5-12, violet for the unliganded
PDE5, red for PDE5-IBMX, light purple for PDE5-icarisid II, and gold for PDE5-sildenafil.
(B) Interactions between 12 (label as WYQ1) and PDE5 residues. The cyan dotted line
represents the disordered M-loop linking helices H14 and H15. The black dotted lines represent
the hydrogen bonds. (C) The electron density for compound 12. The (Fo-Fc) map was
contoured at 3 sigmas.
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Binding and comparison of the PDE5 inhibitors. (A) Structural superposition of PDE5A1-12
(green ribbons and bonds) over PDE5A1-sildenafil (golden ribbons and blue bonds). The M-
loop is disordered in PDE5A-12. (B). detailed viewed of the superposition. Leu804 interacts
with sildenafil but disordered in PDE5A-12. Residues Asn661, Ser663, and Ile665 of the H-
loop interact with sildenafil, but have different location in the PDE5A1-12 structure and do
not contact compound 12. (C) Superposition of compound 12 (green bond) over sildenafil
(gold) and IBMX (cyan). The pyrazolopyrimidinone is co-planed with xanthine of IBMX. The
sulfonamide of 12 shows as much as 1.5 Å positional displacement. (D) A surface presentation
of a small hydrophobic pocket for the binding of the ethoxy group of the PDE5 inhibitors.
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Synthesis of the compounds. Reagents and conditions: (a) SOCl2, DMF, CH2Cl2, reflux; (b)
pyridine, 70°C; (c) tBuOH, tBuOK; (d) ClSO3H, SOCl2, N-methylpiperazine; (e) ClSO3H,
SOCl2, aqueous ammonia; (f) EtONa, EtOH, reflux; (g) and (h) Zn dust; (i) CuI, MeONa,
MeOH, reflux; (j) CuI, EtONa, EtOH, reflux; (k) CuCN, DMF, 150°C; (l) Pd(OAc)2, DPPF,
Cs2CO3, N-methylpiperazine, 120°C; (m) alkyl chloroformates (14–16), DMAP, pyridine, rt.
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Table 1
Statistics on diffraction data and structure refinement
Data collection
Space group P3121




Completeness (%) 91.1 (49.8)*








   Bond (Å) 0.005
   Angle 1.2°
Average B-factor (Å2)
      Protein 38.5 (2523)§
      12 34.1 (26)§
      Waters 39.6 (116)§
      Zn 30.4 (1)§
      Mg 54.4 (1)§
*
The numbers in parentheses are for the highest resolution shell.
‡
The percentage of reflections omitted for calculation of R-free.
§
The number of atoms in the crystallographic asymmetric unit.
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Table 2
IC50 of PDE5 inhibitors with thiophene ring






12 EtO- NH2 0.11
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